Although these molecular alterations are rare in CRC (1–5%), their frequency increases within the RAS-BRAFwt population and may be assessed in this subgroup of patients to predict the favorable response to anti-EGFR blockade. This evidence concerns the gene EGFR and colorectal carcinoma.